how to switch from semaglutide to retatrutide vs semaglutide: complete comparison of weight loss, mechanisms, and results Switching from Semaglutide to Tirzepatide

Evolus has submitted its Premarket Approval application to the FDA and anticipates approval in the second half of 2026

GLP-1s kill hunger

This is especially relevant for individuals at risk of iron deficiency, including menstruating women and those following calorie-restricted diets

1-7 In practical terms, tesamorelin is better supported for a specific medical use involving visceral fat

Certain features warrant prompt medical evaluation: Severe muscle pain or weakness , particularly if accompanied by dark urine, which may indicate rhabdomyolysis (a rare but serious condition involving muscle breakdown) Joint swelling, redness, or warmth , which could suggest inflammatory arthritis or infection (septic arthritis) Pain that significantly impairs daily activities or does not respond to simple analgesia Systemic symptoms such as fever, unexplained weight loss (beyond expected therapeutic effect), or night sweats New or worsening pain following dose escalation, which may require dose adjustment or further investigation Sudden, severe pain in the right upper abdomen , possibly with fever or jaundice, which could indicate gallbladder disease (a recognised risk with GLP-1 receptor agonists) [1] [5] Patients should also seek advice if they experience other concerning adverse effects of Ozempic, including: Persistent nausea or vomiting leading to dehydration or reduced fluid intake Symptoms of hypoglycaemia (tremor, sweating, confusion), particularly if taking Ozempic with insulin or sulphonylureas Severe abdominal pain, which may indicate pancreatitis (a known but uncommon risk with GLP-1 receptor agonists) [1] [5] Visual changes or signs of diabetic retinopathy progression For urgent concerns outside of GP hours, patients should contact NHS 111